PeerVoice Immunology & Infectious Disease Audio

Visit https://www.peervoice.com/WBM860 to view the entire programme with slides. After completing “Living With Multidrug-Resistant HIV: What Clinicians Need to Know”, participants will be able to: Recognise multidrug resistance in people living with HIV (PLWH); Describe the individualised goals of therapy for patients with multidrug-resistant HIV; Appraise strategies to maximise viral suppression of multidrug-resistant HIV, using existing and novel therapies.

Visit https://www.peervoice.com/YAP860 to view the entire programme with slides. After completing “Non-Oncotic Methods for Managing the Milieu of Decompensated Liver Cirrhosis”, participants will be able to: Describe the non-oncotic properties of human albumin and how they relate to the pathology of decompensated cirrhosis; Define the importance of the dosing and administration regimen for human albumin in patients with decompensated cirrhosis and the evidence that supports this approach; Apply practical strategies to identify those patients who will benefit most from a human albumin plus standard medical therapy (SMT) regimen.

Visit https://www.peervoice.com/NHZ860 to view the entire programme with slides. After completing “Clinical Developments in Managing Autoinflammatory Diseases”, participants will be able to: Describe the impact of the latest data and clinical evidence on therapeutic strategies for patients with autoinflammatory diseases; Identify how the clinical features and disease activity associated with autoinflammatory diseases impact patient outcomes, QOL, and treatment considerations; Propose clinical, immunologic, and practical considerations for managing and vaccinating patients with autoinflammatory diseases during the COVID-19 pandemic.

Visit https://www.peervoice.com/BAP860 to view the entire programme with slides. After completing “Therapy for COVID-19: Management Strategies and Clinical Rationale”, participants will be able to: Explain the importance of timing of antiviral initiation in patients with COVID-19; Describe key factors that need to be considered when making a decision to initiate therapy in patients with COVID-19; Identify patients with COVID-19 who are most likely to benefit from antiviral therapy.

Visit https://www.peervoice.com/GFQ860 to view the entire programme with slides. After completing “Going the Distance in HIV: Simplifying ART at Every Stage”, participants will be able to: Explain the rationale for assessing and addressing the need for simplification of ART; Evaluate clinical implications of recent data on simplified ART in a variety of patient scenarios; Develop simplified ART based on individual patient- and disease-related factors.

Visit https://www.peervoice.com/EJM860 to view the entire programme with slides. After completing “Simplifying Screening for Immunodeficiencies: A Practical Strategy Using Calculated Serum Globulin”, participants will be able to: Recognise the impact of delayed diagnosis of antibody deficiency on morbidity and mortality and the need for widespread education and effective screening for primary immunodeficiency (PID) and secondary immunodeficiency (SID); Distinguish the clinical manifestations that would alert the need to screen for PID and how calculated globulin screening can reduce diagnostic delay; Establish how to implement calculated globulin screening for patients with suspected antibody deficiencies.

Visit https://www.peervoice.com/HJS860 to view the entire programme with slides. After completing “Unmet Needs in Familial Mediterranean Fever (FMF): Real-Life Data, the Patient Perspective, and the Role of Anti–IL-1 Therapy”, participants will be able to: Characterise the incidence and impact of colchicine resistance among patients with FMF; Understand disease burden from the perspective of the patient; Analyse the long-term clinical and quality-of-life (QoL) data for anti–IL-1 therapy in colchicine-resistant FMF.

Visit https://www.peervoice.com/JBJ860 to view the entire programme with slides. After completing “GP Empowerment: Eliminating HCV From the Front Line”, participants will be able to: Formulate tailored treatment plans for patients with hepatitis C virus (HCV), depending on patient and disease factors; Use patient-physician communication about HCV and its treatment as a tool to improve patient identification; Apply evidence-based therapies to optimise sustained virological response rates and patient quality of life.

Visit https://www.peervoice.com/TWY860 to view the entire programme with slides. After completing “If You Suspect, Test! The Important First Steps to Preventing the Devastating Consequences of Hepatitis”, participants will be able to: Recognise the need for routine screening for HCV/HBV infection; Apply practical strategies for HCV/HBV screening; Formulate patient-centred approaches for communicating with patients about the need for HCV/HBV screening.

Visit https://www.peervoice.com/VXE860 to view the entire programme with slides. After completing “Can Long-Acting Injectables Make a Difference in HIV?”, participants will be able to: Evaluate the clinical evidence for long-acting injectable therapy for people living with HIV (PLWH); Summarise the potential benefits and limitations of daily vs long-acting therapy in the long-term management of HIV; Create individualised management strategies for therapy for PLWH, taking into account patient needs.